|
T2Candida panel offers survival, cost
savings benefits
June 2015
EDIT CONNECT
SHARING OPTIONS:
LEXINGTON,
Mass.—A study conducted by IMS Health of T2 Biosystems Inc.’s T2Candida Panel was recently published in Future Microbiology. The
study reported that in a 500-bed hospital with an average of 5,100 symptomatic patients at high risk of Candida infection, early
detection—such as with T2Candida—could prevent 60 percent of Candida-related deaths and provide annual cost savings of approximately
$5.8 million.
“We believe these data are extremely compelling and highlight the potentially meaningful benefits of
early detection of Candida with our T2Candida Panel, including significantly reducing hospital costs and, more importantly, saving so many patient
lives,” said T2 Biosystems CEO John McDonough. “The findings from this study support our goal of changing the paradigm in sepsis diagnosis, and
we look forward to the opportunity to help implement this important change for patients, physicians and hospital administrators.”
Code: Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|